drugset / Trial / NCT06762587
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
Not yet recruiting
372 enrolled
Capital Medical University
China-Japan Friendship Hospital · collabChinese Academy of Medical Sciences · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical influenza, evaluating the prophylaxis efficiency of antivirals in a hospital setting.
Timeline
- Start
- 2025-01-05
- Primary completion
- 2025-04-30
- Completion
- 2025-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baloxavir Marboxil | Unknown | 40 mg | — |
| Subject | Baloxavir Marboxil | Unknown | 80 mg | — |
| Subject | Oseltamivir | Small molecule | 75 mg | — |